Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX003 · 2 trials · 1 indication
time of the maximum measured concentration (Tmax)
maximum concentration (Cmax)
area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
elimination rate constant
terminal elimination half life (t½)
clearance (CL)
apparent volume of distribution (Vd)
| Arm | Type | Description |
|---|---|---|
| PRX003 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PRX003 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: 1. Male or female, 18 to 80 years of age (inclusive), body weight range of ≥ 45 kg (99 lbs) to ≤ 120 kg (264 lbs) and a body mass index (BMI) of 18 - 35 kg/m2 2. Provide written informed consent 3. PASI score of ≥12 4. Plaque psoriasis covering ≥10% of BSA 5. s-PGA score of 3 or...
PRX003 is an investigational small molecule being developed for the treatment of psoriasis. It is currently in Phase 1 clinical development and has not been approved by the FDA. Two Phase 1 trials have been completed, including a multiple ascending dose study in subjects with psoriasis.
PRX003 is being developed by Prothena Corporation plc, a biopharmaceutical company traded on NASDAQ under the ticker symbol PRTA. The company is conducting clinical trials for this investigational drug in the United States.
PRX003 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in healthy subjects and one in subjects with psoriasis. The drug is investigational and has not been approved by the FDA for any use.
PRX003 has completed two Phase 1 clinical trials. NCT02458677 was a single ascending dose study in healthy subjects with 40 participants. NCT02630901 was a multiple ascending dose study in subjects with psoriasis with 48 participants. Both trials were conducted in the United States.
PRX003 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a small molecule being studied for psoriasis and is not known to be marketed under any other brand name.